Elamipretide
Elamipretide is a peptide, indexed here under Mitochondrial and longevity-associated peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Mitochondrial and longevity-associated peptides |
| CAS registry number | 736992-21-5[1] |
| PubChem CID | 11764719[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C32H49N9O5[1] |
| Molecular weight | 639.8 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Elamipretide, also reported under the code SS-31, is described in the retrieved literature as a mitochondria-targeting peptide. A 2020 Proceedings of the National Academy of Sciences paper maps its mitochondrial protein interaction landscape, and a 2013 Journal of the American Society of Nephrology paper reports that the mitochondrial-targeted compound re-energises ischaemic mitochondria.
Unlike most compounds in this dataset it carries clinical records. A 2017 Circulation Heart Failure paper reports a randomised study of a mitochondria-targeting peptide in heart failure treatment, and a 2016 Circulation Heart Failure paper reports chronic therapy with it. Preclinical records include a 2018 Aging Cell paper and a 2019 Journal of Neuroinflammation paper reporting mitochondrial, synaptic and memory endpoints. The Drugs@FDA register returned one application record for this generic name, which is recorded verbatim in the regulatory status field on this page; material supplied as a research chemical is not the subject of that application.
[3, 4, 5, 6, 7, 8]Reported mechanism
Described in the retrieved records as a mitochondria-targeting peptide, with a mapped mitochondrial protein interaction landscape rather than a single named receptor.
[3, 4]Stated in the titles of the cited 2020 Proceedings of the National Academy of Sciences and 2013 Journal of the American Society of Nephrology papers.
Targets named in the cited records: inner mitochondrial membrane, cardiolipin.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA215244, marketed as FORZINITY). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Elamipretide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- SS-31
- MTP-131
- Bendavia
Where this page sits
Research records
Cited research records for Elamipretide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- MOTS-c — Mitochondrial and longevity-associated peptides
- Humanin — Mitochondrial and longevity-associated peptides
- Glutathione — Mitochondrial and longevity-associated peptides
Class page: Mitochondrial and longevity-associated peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Elamipretide?
Elamipretide, also reported under the code SS-31, is described in the retrieved literature as a mitochondria-targeting peptide. A 2020 Proceedings of the National Academy of Sciences paper maps its mitochondrial protein interaction landscape, and a 2013 Journal of the American Society of Nephrology paper reports that the mitochondrial-targeted compound re-energises ischaemic mitochondria.
Which class is Elamipretide indexed under?
Elamipretide is indexed under Mitochondrial and longevity-associated peptides. This class groups peptides whose retrieved literature concerns mitochondrial function or ageing endpoints.
What does the FDA application register show for Elamipretide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA215244, marketed as FORZINITY). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 11764719, Elamipretide. PubChem, National Library of Medicine (2026). pubchem:11764719
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA215244. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ss-31
- Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences of the United States of America (2020). pmid:32554501
- The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology : JASN (2013). pmid:23813215
- Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation. Heart failure (2017). pmid:29217757
- Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circulation. Heart failure (2016). pmid:26839394
- Treatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice. Aging cell (2018). pmid:29405550
- Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Journal of neuroinflammation (2019). pmid:31747905
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.